参考文献

［1］ MISE K, IMAMURA M, YAMAGUCHI S, et al. Identification of novel urinary biomarkers for predicting renal prognosis in patients with type 2 diabetes by glycan profiling in a multicenter prospective cohort study: U-care study 1 [J]. Diabetes Care, 2018, 41 (8): 1765-1775.

［2］ MOLITCH M E, ADLER A I, FLYVBJERG A, et al. Diabetic kidney disease: A clinical update from kidney disease: Improving global outcomes [J]. Kidney Int, 2015, 87 (1): 20-30.

［3］ ZHANG L, LONG J, JIANG W, et al. Trends in chronic kidney disease in china [J]. N Engl J Med, 2016, 375 (9): 905-906.

［4］ 李静, 梁田田, 王文健. 糖尿病肾病的早期诊断 [J]. 中华肾脏病杂志, 2017, 6): 470-475.

［5］ AMERICAN DIABETES ASSOCIATION. Standards of medical care in diabetes-2019 [J]. Diabetes Care, 2019, 42 (Suppl 1): S1-187.

［6］ CHANG D, WANG Y C, XU T T, et al. Noninvasive identification of renal hypoxia in experimental myocardial infarctions of different sizes by using bold MR imaging in a mouse model [J]. Radiology, 2018, 286 (1): 129-139.

［7］ PRUIJM M, MILANI B, PIVIN E, et al. Reduced cortical oxygenation predicts a progressive decline of renal function in patients with chronic kidney disease [J]. Kidney Int, 2018, 93 (4): 932-940.

［8］ LEE C H, CHEUNG C Y Y, WOO Y C, et al. Prospective associations of circulating adipocyte fatty acid-binding protein levels with risks of renal outcomes and mortality in type 2 diabetes [J]. Diabetologia, 2019, 62 (1): 169-177.

［9］ BARR E L M, BARZI F, HUGHES J T, et al. High baseline levels of tumor necrosis factor receptor 1 are associated with progression of kidney disease in indigenous australians with diabetes: The eGFR follow-up study [J]. Diabetes Care, 2018, 41 (4): 739-747.

［10］ XIE Y, BOWE B, LI T, et al. Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus [J]. Kidney Int, 2018, 93 (3): 741-752.

［11］ CARDOSO C R L, LEITE N C, SALLES G C, et al. Aortic stiffness and ambulatory blood pressure as predictors of diabetic kidney disease: A competing risks analysis from the rio de janeiro type 2 diabetes cohort study [J]. Diabetologia, 2018, 61 (2): 455-465.

［12］ ISHII T, FURUYA F, TAKAHASHI K, et al. Angiopoietin-like protein 2 promotes the progression of diabetic kidney disease [J]. J Clin Endocrinol Metab, 2019, 104 (1): 172-180.

［13］ RASMUSSEN D G K, HANSEN T W, VON SCHOLTEN B J, et al. Higher collagen vi formation is associated with all-cause mortality in patients with type 2 diabetes and microalbuminuria [J]. Diabetes Care, 2018, 41 (7): 1493-1500.

［14］ NOWAK N, SKUPIEN J, SMILES A M, et al. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development [J]. Kidney Int, 2018, 93 (5): 1198-1206.

［15］ HEINZEL A, KAMMER M, MAYER G, et al. Validation of plasma biomarker candidates for the prediction of egfr decline in patients with type 2 diabetes [J]. Diabetes Care, 2018, 41 (9): 1947-1954.

［16］ TAN K C B, CHEUNG C L, LEE A C H, et al. Galectin-3 is independently associated with progression of nephropathy in type 2 diabetes mellitus [J]. Diabetologia, 2018, 61 (5): 1212-1219.

［17］ DOI T, MORIYA T, FUJITA Y, et al. Urinary igg4 and smad1 are specific biomarkers for renal structural and functional changes in early stage of diabetic nephropathy [J]. Diabetes, 2018，67（5）：986-993.